| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 03/24/2004 | CN1142912C Amide derivs, useful as inhibitors for production of cytokines |
| 03/24/2004 | CN1142777C Use of oxazolidinone derivative for treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy |
| 03/24/2004 | CN1142753C Skin patches for providing testosterone |
| 03/24/2004 | CN1142718C Heath-care food for joints of pet |
| 03/23/2004 | US6710088 Inorganic ion receptor-active compounds |
| 03/23/2004 | US6710075 Compounds having a cyclopentabenzofuran core shown to exhibit potent cytotoxic and cytostatic effects on cancer cell growth and viability |
| 03/23/2004 | US6710067 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/23/2004 | US6710054 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 03/23/2004 | US6710052 Anticancer agents |
| 03/23/2004 | US6710048 Selective inhibitors of vascular endothelial growth factor receptor tyrosine kinase; to treat solid-tumor cancers, angiogenesis, diabetic retinopathy, rheumatoid arthritis, endometriosis and psoriasis |
| 03/23/2004 | US6709831 DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof |
| 03/23/2004 | CA2263319C Quinazoline derivatives and pharmaceutical compositions containing them |
| 03/18/2004 | WO2004022761A1 Retroviral vector and stable packaging cell lines |
| 03/18/2004 | WO2004022716A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | WO2004022569A1 Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 03/18/2004 | WO2004022557A1 Novel benzonaphthyridines |
| 03/18/2004 | WO2004022553A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE |
| 03/18/2004 | WO2004022551A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | WO2004022529A2 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | WO2004022526A1 Cathepsin cysteine protease inhibitors |
| 03/18/2004 | WO2004022525A1 Amide derivatives and their use as chloride channel blockers |
| 03/18/2004 | WO2004022095A1 Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy |
| 03/18/2004 | WO2004022089A1 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 03/18/2004 | WO2004022078A1 Pharmaceutical kits comprising mesenchymal stem cells |
| 03/18/2004 | WO2004022032A2 Pharmaceutical dosage form comprising a sulfite compound |
| 03/18/2004 | WO2004007697A3 Methods of implanting mesenchymal stem cells for tissue repair and formation |
| 03/18/2004 | WO2003099289A3 Compositions and their uses for alleviating pain |
| 03/18/2004 | WO2003099192A3 Bis-aromatic alkanols |
| 03/18/2004 | WO2003084936A3 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| 03/18/2004 | WO2003066081A3 Bmp inhibitors for the treatment of spondyloarthropathies |
| 03/18/2004 | WO2003028630A3 Methods and compositions for modulating interleukin-21 receptor activity |
| 03/18/2004 | WO2003018535A3 Novel aminobenzoephenones |
| 03/18/2004 | WO2002102972A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 03/18/2004 | WO2002095034A9 A retinoic acid metabolizing cytochrome p450 |
| 03/18/2004 | US20040054193 Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) |
| 03/18/2004 | US20040054186 Autoimmune diseases; anticancer agents; antiproliferative agents; skin disorders |
| 03/18/2004 | US20040054183 Thienopyridine derivatives, their production and use |
| 03/18/2004 | US20040054179 Antiallergens; skin disorders; antitumor agents; tyrosine kinase inhibitor |
| 03/18/2004 | US20040054172 Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids |
| 03/18/2004 | US20040054149 Modified proteolytic enzyme for treatment of osteoarthritis |
| 03/18/2004 | US20040054145 Truncated cd200 |
| 03/18/2004 | US20040054143 Vegf peptides and their use for inhibiting angiogenesis |
| 03/18/2004 | US20040054133 Multiple sclerosis-related superantigen |
| 03/18/2004 | US20040054001 For preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB, particularly psoriasis |
| 03/18/2004 | US20040053983 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase |
| 03/18/2004 | US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases |
| 03/18/2004 | US20040053973 Substituted 1,3-thiazole compounds, their production and use |
| 03/18/2004 | US20040053958 Di and trifluoro-triazolo-pyridines anti-inflammatory compounds |
| 03/18/2004 | US20040053957 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization |
| 03/18/2004 | US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives |
| 03/18/2004 | US20040053953 Treatment of chemokine mediated diseases |
| 03/18/2004 | US20040053951 Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use |
| 03/18/2004 | US20040053943 Novel compounds |
| 03/18/2004 | US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors |
| 03/18/2004 | US20040053931 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors |
| 03/18/2004 | US20040053925 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 03/18/2004 | US20040053924 Reacting pyrrolo(2,3-d)pyrimidin-4-one derivative containing a leaving group with a aromatic or heteroaromatic amine, hydroxy, marcaptan etc. in presence of a polar solvent and a catalyst |
| 03/18/2004 | US20040053921 Compounds useful as reversible inhibitors of cysteine proteases |
| 03/18/2004 | US20040053920 Administering to a patient suffering from caspase mediated diseses, an effective amount of a mono,bi or tri-heterocyclic ring containing nitrogen atom attached to ester or thioester to form carbamate group, as caspase inhibitor |
| 03/18/2004 | US20040053919 Administering a patient suffering from arthritic diseases, a 1,4-benzodiazapine or a 1,4-benzothiazepine derivative for treating such degenerative joint diseases |
| 03/18/2004 | US20040053915 Pyrazolopyridine derivatives |
| 03/18/2004 | US20040053908 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective |
| 03/18/2004 | US20040053900 Administering to a mammal a combination of cyclooxygenase-2 inhibitor and aromatase inhibitor for the prevention, or inhibition of a neoplasia, a neoplasia-related disorder, or osteoporosis in mammal in need |
| 03/18/2004 | US20040053898 For organ specific therapy; for treatment of menopausal symptoms, hormone-deficiency diseases and neurodegenerative diseases |
| 03/18/2004 | US20040053890 Naphthalene derivatives |
| 03/18/2004 | US20040053885 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 03/18/2004 | US20040053884 Comprises N-acylated hydroxyproline derivatives and glycosaminoglycans (chondroitin sulfate); for treatment of arthritis |
| 03/18/2004 | US20040053867 Nucleotide sequences that code for transport proteins; modulation of excitatory amino acids or signal tranduction; detoxification |
| 03/18/2004 | US20040053852 Preventing desensitization of receptors |
| 03/18/2004 | US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 03/18/2004 | US20040053845 Modified peptides as therapeutic agents |
| 03/18/2004 | US20040053844 Peptide and osteogenetic accelerator |
| 03/18/2004 | US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents |
| 03/18/2004 | US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds |
| 03/18/2004 | US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders |
| 03/18/2004 | US20040052873 Bioavailability / bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 03/18/2004 | US20040052870 Cyclooxygenase (COX-2) inhibitors; for treatment/prevention of inflammation; nutraceuticals; for treatment of nervous system disorders |
| 03/18/2004 | US20040052869 Orally ingestible preparation of mistletoe lectins and method |
| 03/18/2004 | US20040052860 Bone health compositions derived from milk |
| 03/18/2004 | CA2538187A1 Pharmaceutical kits comprising mesenchymal stem cells |
| 03/18/2004 | CA2498297A1 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 03/18/2004 | CA2497901A1 Furan or thiophene derivative and medicinal use thereof |
| 03/18/2004 | CA2495939A1 Cathepsin cysteine protease inhibitors |
| 03/18/2004 | CA2495284A1 Diarylurea derivatives and their use as chloride channel blockers |
| 03/18/2004 | CA2493974A1 Pharmaceutical dosage form comprising a sulfite compound |
| 03/17/2004 | EP1398036A1 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 03/17/2004 | EP1398033A2 Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis |
| 03/17/2004 | EP1397492A2 Modified and stabilized gdf propeptides and uses thereof |
| 03/17/2004 | EP1397364A1 Novel pyrrole derivatives as pharmaceutical agents |
| 03/17/2004 | EP1397363A1 5-ethyl-imidazotriazinones |
| 03/17/2004 | EP1397361A1 Carboline derivatives as pdev inhibitors |
| 03/17/2004 | EP1397360A1 Azaindoles |
| 03/17/2004 | EP1397359A1 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| 03/17/2004 | EP1397356A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 03/17/2004 | EP1397355A1 Pyridyl cyanoguanidine compounds |
| 03/17/2004 | EP1397340A2 Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/17/2004 | EP1397172A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397170A1 Safety shield system for prefilled syringes |
| 03/17/2004 | EP1397156A2 Oral administration of parathyroid hormone and calcitonin |
| 03/17/2004 | EP1397153A2 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |